Release issued 1st December 2006

York, UK, 01 December 2006 - With deals increasing in terms of number and value, partnering at early stage development is now an integral component of pharmaceutical and biotech business strategy. Deal complexity has advanced in financial reward structures and exchange of non-monetary capabilities.

To follow this interest in early stage dealmaking, Pharmalicensing has revised and updated its successful Early Stage and Discovery Deals report. The new report analyzes early stage dealmaking trends and discusses the basics of dealmaking structures, covering payments terms and deal valuations. Updated with in-depth contracts, case stud ies and new deal data the report reflects the present status of early stage dealmaking.

The report includes an updated section of today’s early stage deal strategies and structures, featuring an extensive collection of supporting case studies from 2006, which bring into focus the current methods employed by companies to achieve the best deal.

A full data analysis of early stage deal terms and trends in the final section of the report breaks down the headline values of deals allowing readers to gain an insight into individual payments and rates.

For more information on 'Early Stage and Discovery Deals: Strategy, Structure and Payment Terms 2^nd Edition' or other reports, go to store.pharmalicensing.com, or contact the reports team on tel: +44 1904 520460 or email: sales@pharmalicensing.com

Pharmalicensing Ltd (pharmalicensing.com), based in York, UK, is the leading online global resource for partnering, licensing and business development within the life science and biopharmaceutical industry.

Contact: Johan Ohlsson, Strategic Analyst, Business Development (johan.ohlsson@pharmalicensing.com; Tel +44 1904 520491) ;

(4th January 2008) UTEK Corporation Acquires Pharmalicensing, Ltd.

(25th July 2007) Pharmalicensing launches 3rd edition of top selling licensing agreement report

(23rd July 2007) Comprehensive consultancy support for your licensing

(15th January 2007) New report from Pharmalicensing highlights the R&D opportunities in China

(6th June 2006) Pharmalicensing re-launches reports on the top 50 biopharmaceutical companies